This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spears, C. P. Articles by Corbett, T. H. Search for Related Content PubMed PubMed Citation Articles by Spears, C. P. Articles by Corbett, T. H.

In Vivo Kinetics of Thymidylate Synthetase Inhibition in 5-Fluorouracil-sensitive and -resistant Murine Colon Adenocarcinomas¹

Cancer Research Laboratories, University of Southern California Comprehensive Cancer Center, Los Angeles, California 90033 [C. P. S., A. H. S., C. H.]; Childrens Hospital of Los Angeles, Los Angeles, California 90027 [R. G. M.]; and Southern Research Institute, Birmingham, Alabama 35255 [T. H. C.]

The predictive utility of several biochemical parameters of 5-fluorouracil (5-FUra) action was evaluated in four murine colonic adenocarcinomas: 5-FUra-sensitive Tumor 38 and 5-FUra-resistant Tumors 07/A, 51, and 06/A. Thymidylate synthetase (TS) was determined by a tritiated 5-fluoro-2'-deoxyuridylate (FdUMP)-binding assay. Bolus 5-FUra (80 mg/kg, i.p.) administration caused in all tumors a rapid decrease in free TS levels. Only Tumor 38, however, showed inhibition of TS to undetectable (<0.05 pmol/g) levels, which lasted up to 6 hr after treatment; correction for dissociation of endogenous TS: FdUMP:folate ternary complex during the TS assay was required. Total TS (free enzyme plus ternary complex) was determined with experimental conditions that achieved quantitative recovery of free TS from ternary complex. By 48 hr after 5-FUra, Tumor 38 showed a decrease in total TS proportional to the estimated log kill/dose of 5-FUra; in contrast, the resistant tumors showed no such decrease from pretreatment levels. Assay of FdUMP showed that the free nucleotide was formed rapidly in all tumors in excess over available TS-binding sites. However, tumor sensitivity did not correlate with peak or residual FdUMP levels or with deoxyuridylate levels, which were low and remained so in all tumors. Tumor sensitivity to 5-FUra also could not be explained by the small differences among the tumors in total perchloric acid-soluble metabolites of 5-FUra or drug incorporation into RNA. We conclude from these data that levels of free TS in the tumor after 5-FUra treatment are predictive of chemotherapeutic response in these murine models of human colonic adenocarcinoma.

¹ Supported by Grant CA 27,610 from the National Cancer Institute, NIH, and a grant from the Hoffmann-LaRoche Foundation. Previously unpublished chemotherapy results were supported by Contract NO1-CM-97309 from the Division of Cancer Treatment, National Cancer Institute, NIH.

² To whom requests for reprints should be addressed, at the USC Cancer Center, 1721 Griffin Avenue, Los Angeles, Calif. 90031.

Received 7/10/81. Accepted 11/ 2/81.

This article has been cited by other articles:

				Y. Sakurai, I. Yoshida, S. Kamoshida, K. Inaba, J. Isogaki, Y. Komori, I. Uyama, and Y. Tsutsumi Effects of Combined Administration of DPD-Inhibitory Oral Fluoropyrimidine, S-1, Plus Paclitaxel on Gene Expressions of Fluoropyrimidine Metabolism-Related Enzymes in Human Gastric Xenografts Ann. Surg. Oncol., August 1, 2008; 15(8): 2301 - 2309. [Abstract] [Full Text] [PDF]

				T. Okabe, I. Okamoto, S. Tsukioka, J. Uchida, T. Iwasa, T. Yoshida, E. Hatashita, Y. Yamada, T. Satoh, K. Tamura, et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase Mol. Cancer Ther., March 1, 2008; 7(3): 599 - 606. [Abstract] [Full Text] [PDF]

				H. F. Nijhout, M. C. Reed, P. Budu, and C. M. Ulrich A Mathematical Model of the Folate Cycle: NEW INSIGHTS INTO FOLATE HOMEOSTASIS J. Biol. Chem., December 31, 2004; 279(53): 55008 - 55016. [Abstract] [Full Text] [PDF]

				Y. Mizutani, H. Wada, O. Yoshida, M. Fukushima, M. Nonomura, M. Nakao, and T. Miki Significance of Thymidylate Synthase Activity in Renal Cell Carcinoma Clin. Cancer Res., April 1, 2003; 9(4): 1453 - 1460. [Abstract] [Full Text] [PDF]

				G. Gribaudo, L. Riera, D. Lembo, M. De Andrea, M. Gariglio, T. L. Rudge, L. F. Johnson, and S. Landolfo Murine Cytomegalovirus Stimulates Cellular Thymidylate Synthase Gene Expression in Quiescent Cells and Requires the Enzyme for Replication J. Virol., June 1, 2000; 74(11): 4979 - 4987. [Abstract] [Full Text]

				M. Nishiyama, W. Yamamoto, J.-S. Park, R. Okamoto, H. Hanaoka, H. Takano, N. Saito, M. Matsukawa, T. Shirasaka, and M. Kurihara Low-Dose Cisplatin and 5-Fluorouracil in Combination CanRepress Increased Gene Expression of Cellular Resistance Determinants to Themselves Clin. Cancer Res., September 1, 1999; 5(9): 2620 - 2628. [Abstract] [Full Text] [PDF]

				M. E. Kitchens, A. M. Forsthoefel, Z. Rafique, H. T. Spencer, and F. G. Berger Ligand-mediated Induction of Thymidylate Synthase Occurs by Enzyme Stabilization. IMPLICATIONS FOR AUTOREGULATION OF TRANSLATION J. Biol. Chem., April 30, 1999; 274(18): 12544 - 12547. [Abstract] [Full Text] [PDF]

				Y. Ishikawa, T. Kubota, Y. Otani, M. Watanabe, T. Teramoto, K. Kumai, M. Kitajima, T. Takechi, H. Okabe, and M. Fukushima Dihydropyrimidine Dehydrogenase Activity and Messenger RNA Level May Be Related to the Antitumor Effect of 5-Fluorouracil on Human Tumor Xenografts in Nude Mice Clin. Cancer Res., April 1, 1999; 5(4): 883 - 889. [Abstract] [Full Text] [PDF]

				S. Cao, K. Lu, K. Toth, H. K. Slocum, T. Shirasaka, and Y. M. Rustum Persistent Induction of Apoptosis and Suppression of Mitosis as the Basis for Curative Therapy with S-1, an Oral 5-Fluorouracil Prodrug in a Colorectal Tumor Model Clin. Cancer Res., February 1, 1999; 5(2): 267 - 274. [Abstract] [Full Text] [PDF]

				E. Chu, J. L. Grem, P. G. Johnston, and C. J. Allegra New Concepts for the Development and Use of Antifolates Oncologist, August 1, 1996; 1(4): 255 - 259. [Abstract] [Full Text] [PDF]

				E Chu, J. Grem, P. Johnston, and C. Allegra New concepts for the development and use of antifolates Stem Cells, January 1, 1996; 14(1): 41 - 46. [Abstract]